Ethosuximide (Epilepsy)

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S6495
R17808		 Bànhidy (Ethosuximide), 2011 Cardiovascular congenital abnormalities throughout pregnancy case control unexposed, sick Adjustment: No Matched 2.11 [0.04;124.53] C 0/   5/15 5 0
ref
S6065
R15776		 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 Cardiac 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 6.21 [0.32;122.15] C 0/12   4/647 4 12
ref
Total 2 studies 4.26 [0.38;47.27] 9 12
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Ethosuximide), 2011Bànhidy, 2011 1 2.11[0.04; 124.53]5-35%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 6.21[0.32; 122.15]41265%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 4.26[0.38; 47.27]9120.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Ethosuximide; 2: Ethosuximide) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 6.21[0.32; 122.15]412 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 1 case control studiescase control studies 2.11[0.04; 124.53]5- -NABànhidy (Ethosuximide), 2011 1 Type of controls unexposed, sickunexposed, sick 2.11[0.04; 124.53]5- -NABànhidy (Ethosuximide), 2011 1 exposed to other treatment, sickexposed to other treatment, sick 6.21[0.32; 122.15]412 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 4.26[0.38; 47.27]9120%NABànhidy (Ethosuximide), 2011 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 2 MatchedMatched 2.11[0.04; 124.53]5- -NABànhidy (Ethosuximide), 2011 1 All studiesAll studies 4.26[0.38; 47.27]9120%NABànhidy (Ethosuximide), 2011 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 2.11[0.04; 124.53]5- -NABànhidy (Ethosuximide), 2011 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 6.21[0.32; 122.15]412 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 10.510.01.0